Neuroendocrine transdifferentiation induced by VPA is mediated by PPARγ activation and confers resistance to antiblastic therapy in prostate carcinoma

Prostate

Volumn 68, Issue 6, 2008, Pages 588-598

  Angelucci, Adriano ^a   Muzi, Paola ^b   Cristiano, Loredana ^a   Millimaggi, Danilo ^b   Cimini, AnnaMaria ^a   Dolo, Vincenza ^b   Miano, Roberto ^c   Vicentini, Carlo ^a   Cerù, Maria Paola ^a   Bologna, Mauro ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

tubulin III; Bcl 2; cis platinum; Histone deacetylase inhibitors; Secretory neuron specific enolase

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; FLUORESCENCE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; XENOGRAFT;

ADENOCARCINOMA; ANILIDES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG COMBINATIONS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MICE; MICE, NUDE; NEUROSECRETORY SYSTEMS; PPAR GAMMA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42949125779     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20708     Document Type: Article

References (32)

1. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006;68(1):2-8.
2. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27(7):683-687.
3. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997;80(2):287-290.
4. Yamada Y, Nakamura K, Aoki S, Taki T, Naruse K, Matsubara H, Tobiume M, Zennami K, Katsuda R, Honda N. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer. BJU Int 2007;99(1):189-195.
5. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 1999;154(2):543-551.
6. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002;53(2):118-123.
7. Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 2000;196(5):277-284.
8. Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Begin LR, Aprikian AG. Vascular endothelial growth factor and signaling in the prostate: More than angiogenesis. Mol Cell Endocrinol 2002;189(1-2):169-179.
9. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51(4):585-589.
10. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17(9):1726-1737.
11. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64(3):1079-1086.
12. Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G, Bernardini S. Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs 2006;17(10):1141-1150.
13. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006;66(14):7237-7244.
14. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: Enhancement by combination with interferon-alpha. Int J Oncol 2002;20(1):97-106.
15. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58(15):3344-3352.
16. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003;9(1):1-9.
17. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005;65(4):1561-1569.
18. Lampen A, Carlberg C, Nau H. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives. Eur J Pharmacol 2001;431(1):25-33.
19. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005;47(2):147-155.
20. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 2001;1539(1-2):28-43.
21. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5(4-5):245-253.
22. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51.
23. Newmark HL, Lupton JR, Young CW. Butyrate as a differentiating agent: Pharmacokinetics, analogues and current status. Cancer Lett 1994;78(1-3):1-5.
24. Yang J, Kawai Y, Hanson RW, Arinze IJ. Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem 2001;276(28):25742-25752.
25. Orchel A, Dzierzewicz Z, Parfiniewicz B, Weglarz L, Wilczok T. Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig Dis Sci 2005;50(3):490-498.
26. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996;7(7):766-773.
27. McMillan L, Butcher SK, Pongracz J, Lord JM. Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: Differential activation of PKC and MAP kinases. Br J Cancer 2003;88(5):748-753.
28. Weber SM, Scarim AL, Corbett JA. PPARgamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2004;286(3):E329-E336.
29. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004;18(5):528-540.
30. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000;97(20):10990-10995.
31. Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: Function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 2007;212(1):1-12.
32. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83(6):841-850.